DWA
AKRO

Dorsey Wright & Associates’s Akero Therapeutics AKRO Stock Holding History

Dorsey Wright & Associates’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-238
Closed -$7K – 305
2020
Q3 		$7K Buy
+238
New +$8.32K ﹤0.01% 257

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dorsey Wright & Associates's AKRO Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of Akero Therapeutics (AKRO) in Q4 2020, closing a stake of 238 shares — an estimated $7K sold.

Dorsey Wright & Associates first reported a position in AKRO in Q3 2020 and held it in 1 quarter. The position peaked at $7K in Q3 2020. 94 funds tracked by Wall St. Rank hold AKRO as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining Akero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 238 Akero Therapeutics shares in Q4 2020, an estimated $7K.
  • Dorsey Wright & Associates first reported a position in Akero Therapeutics in Q3 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Akero Therapeutics position peaked at $7K in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.